Caspase-1 is not involved in experimental hepatitis in mouse  by van Molle, Wim et al.
Caspase-1 is not involved in experimental hepatitis in mouse
Wim van Molle, Peter Brouckaert, Claude Libert*
Department of Molecular Biology, Flanders Interuniversity Institute for Biotechnology and University of Ghent, K.L. Ledeganckstraat 35,
B-9000 Ghent, Belgium
Received 17 December 1998; received in revised form 18 January 1999
Abstract Experimental hepatitis induced by tumor necrosis
factor in D-(+)-galactosamine-sensitized mice or by an agonistic
anti-Fas antibody in normal mice is accompanied by dramatic
apoptosis of hepatocytes. Apoptosis is the final result of
activation of a cascade of caspases. We used caspase-1^/^ mice,
generated by gene targeting, to study the role of this protease in
TNF- and anti-Fas-induced lethal hepatitis. We found that
mutant mice exhibited the typical caspase-1^/^ phenotype, since
they resisted to a lethal injection of LPS and released no
interleukin-1L in the circulation, in contrast to wild-type
littermates. When caspase-1^/^ mice were challenged with
different doses of tumor necrosis factor/D-(+)-galactosamine or
with anti-Fas, no increased survival was observed compared with
control mice. Furthermore, apoptosis in the livers of these mice
and serum levels of alanine aminotransferase were not reduced.
These data indicate that caspase-1 deficiency does not lead to
reduced apoptosis in these models, either because caspase-1 is
irrelevant in this model or because of functional redundancy.
z 1999 Federation of European Biochemical Societies.
Key words: Apoptosis; Caspase; Hepatitis ;
Tumor necrosis factor
1. Introduction
Induction of liver failure by tumor necrosis factor (TNF)
has been recognized as being a major dose-limiting toxicity,
hampering the use of TNF as an antitumor drug. Several
model systems have been developed to study the mechanism
by which TNF induces necrosis of the liver. It was found that
TNF injection in mice sensitized by D-(+)-galactosamine
(GalN) leads to a speci¢c lethal hepatitis, involving massive
induction of apoptosis of hepatocytes [1,2] and which resem-
bles very closely the lethal hepatitis induced by triggering Fas/
CD95/APO-1 [3], a member of the TNF-receptor superfamily.
Apoptosis has been found to be the result of cleavage of
essential substrates and chromosomal DNA by activated casp-
ases, which are aspartate-speci¢c proteases [4]. Caspase-1 or
homologues were found to be involved in TNF- and anti-Fas-
induced apoptosis and to activate other caspases [5]. Recently,
two groups independently described the generation of caspase-
13=3 mice by gene targeting [6,7]. These mice had developed
normally, which is surprising since apoptosis is an essential
event during the development of, for example, the extremities.
A reduced response of T-cells to anti-Fas-induced apoptosis
was found [6] along with a resistance to an otherwise lethal
injection of LPS [7]. Recently, it was shown that caspase-1 is
responsible for activating interferon-Q inducing factor, also
known as interleukin-18, and that caspase-13=3 mice fail to
produce interferon-Q after stimulation with LPS [8].
We were interested to know to what extent caspase-1 is
involved in the induction of apoptosis in the liver, after a
challenge with TNF or anti-Fas. We used caspase-13=3 mice
and studied the survival, metabolic parameters and death as
an endpoint. We conclude that the absence of caspase-1 does
not lead to reduced apoptosis in both the TNF/GalN and the
anti-Fas model.
2. Materials and methods
2.1. Animals
The female caspase-13=3 mice [7] and control animals were a kind
gift of Dr. T. Seshadri (BASF Bioresearch Corporation, Worcester,
MA, USA) and were bred as homozygotes at our facilities. Mice were
used at the age of 8^15 weeks. The animals were housed in a temper-
ature-controlled, air-conditioned room with 12 h light/dark cycles,
and received water and food ad libitum.
2.2. Reagents
Murine TNF (mTNF), produced and puri¢ed to homogeneity in
our laboratory, had a speci¢c activity of 2.3U108 IU/mg: the endo-
toxin contamination was 0.2 ng/mg protein. The endotoxin levels were
assessed with a chromogenic Limulus amoebocyte lysate assay (Coat-
est : Chromogenix, Stockholm, Sweden). LPS (E. coli O111:B4) was
purchased from Difco Laboratories (Detroit, MI, USA), GalN was
obtained from Sigma Chemical (St. Louis, MO, USA). Agonistic
monoclonal hamster anti-mouse Fas was purchased from PharMingen
(San Diego, CA, USA) and had an endotoxin level of 0.05 ng/mg
protein, according to the manufacturer.
2.3. Injections and blood collections
Reagents were diluted in LPS-free PBS before use. Intraperitoneal
(i.p.) injections had a volume of 0.5 ml and intravenous (i.v.) injec-
tions were given in a volume of 0.2 ml. Blood for alanine amino-
transferase (ALT) was taken from the retro-orbital plexus under ether
anesthesia. Serum was prepared by allowing blood to clot for 30 min
at 37‡C and 1 h at 4‡C, followed by centrifugation at 16 000Ug.
2.4. Assays
Serum ALT was determined using an enzymatic/colorimetric ALT
kit (Sigma Chemical). Interleukin-1L (IL-1L) concentrations in the
serum were estimated using a D10 bioassay [9].
2.5. Tests for apoptosis
Apoptosis was quanti¢ed in a cell death detection ELISA kit
(Boehringher Mannheim, Mannheim, Germany). Before excision,
livers were perfused for 10 s with perfusion bu¡er (50 mM phosphate,
120 mM NaCl, 10 mM EDTA, pH 7.4). A 20% homogenate (w/w)
was made in the same bu¡er with a homogenizer (Heidolph-Elektro,
Kelheim, Germany: model RZR 2020 at position II-10) and centri-
fuged for 20 min at 13 000Ug. The supernatant of approximately
25 Wg of liver was used in the ELISA as described previously [2].
Internucleosomal DNA cleavage was con¢rmed by gel electrophoresis.
DNA was prepared from 500 Wl of liver homogenate. The proteins
were removed once with phenol/chloroform/isoamylalcohol (50/48/2)
and once with chloroform/isoamylalcohol (24/1). DNA was precipi-
tated overnight with 5 M ammoniumacetate and ethanol at 320‡C.
DNA was resolved in Tris/EDTA and RNA was removed by RNase-
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H treatment. The samples were then analyzed by gel electrophoresis in
a 1.8% agarose gel, followed by ethidium bromide staining.
2.6. Statistics
Mean values (and S.D.) were compared using an unpaired Student’s
t-test, with Welch’s correction in the case of non-homogeneous var-
iances. Survival curves (Kaplan-Meier plots) were compared using a
chi2 test.
3. Results
3.1. Caspase-13=3 mice are resistant to a lethal challenge with
LPS and produce no mature IL-1L
It was reported that caspase-13=3 mice are resistant to a
systemic in£ammatory response syndrome induced by LPS [7].
Furthermore, these mice do not produce mature IL-1L. In our
¢rst experiment, we intended to repeat these ¢ndings. There-
fore caspase-13=3 mice and wild-type (wt) control mice were
challenged i.p. with 800 Wg LPS. This dose and LPS type are
identical as in the original paper [7]. 4 h After the challenge,
blood was withdrawn for IL-1L determinations and lethality
was assessed up to 72 h after the challenge. In Table 1 we
demonstrate that in contrast to wt mice, caspase-13=3 mice
produced no detectable IL-1L. Furthermore, all wt mice died
to the challenge while all caspase-13=3 mice survived and
displayed no signs of distress. This experiment con¢rmed the
results obtained by Li et al. [7].
3.2. Caspase-1 is not essential for the lethality induced by
TNF+GalN or anti-Fas
We and others described that TNF+GalN causes massive in
vivo apoptosis of hepatocytes in mice [2,10]. Similar observa-
tions were also made after a challenge with an agonistic anti-
Fas antibody [2,3]. To test the possible in vivo role of caspase-
1, caspase-13=3 mice and wt control mice were challenged i.p.
with 20 mg GalN in combination with di¡erent doses of
mTNF, 0.1 and 0.5 Wg. The survival was assessed up to 48
h after the challenge. Fig. 1 demonstrates that 0.1 Wg is a
sublethal dose, both for wt and caspase-13=3 mice. No di¡er-
ence in ¢nal lethality was recorded (Ps 0.05) for the two
doses. Wt and caspase-13=3 mice were treated i.v. with 5 or
15 Wg anti-Fas. Lethality was followed up to 24 h after the
challenge. In Fig. 2, we demonstrate that 5 Wg anti-Fas causes
partial lethality in both types of mice. 100% lethality is ob-
tained with 15 Wg anti-Fas. Also in this model, no signi¢cant
di¡erences between wt and caspase-13=3 mice were found
(Ps 0.05). These results demonstrate that the absence of
caspase-1 has not led to a reduced lethal response induced
either by TNF+GalN or by anti-Fas.
3.3. The absence of caspase-1 does not prevent apoptosis
induced by TNF+GalN or anti-Fas
We were interested to know whether apoptosis can still
occur in the hepatocytes since an in vitro involvement of
caspase-1 in induction of apoptosis by TNF or anti-Fas had
been described [11,12]. Caspase-13=3 and wt mice were chal-
lenged i.p. with 0.5 Wg mTNF+20 mg GalN or i.v. with 15 Wg
anti-Fas. To check the absence of apoptosis, mice were also
injected with 20 mg GalN or 0.5 Wg mTNF. 5 h (anti-Fas) or
8 h (TNF/GalN) after the challenge, blood was collected for
ALT measurements and mice were killed to remove livers for
determination of DNA fragmentation. At the moment livers
were excised, it was clear that necrosis had occurred both in
FEBS 21581 22-2-99
Table 1
Sensitivity of wt and caspase-13=3 mice, and induction of IL-1L after a lethal challenge with LPS
Challenge Mice IL-1L (pg/ml) Lethality
800 Wg LPS i.p. Caspase-1= 474 þ 208 6/6
800 Wg LPS i.p. Caspase-13=3 Not detectable 0/6
IL-1L (mean þ S.D.) was measured in the serum, collected 4 h after the challenge. Lethality (deaths/total) was scored 72 h after the challenge
(no further deaths occurred).
Fig. 1. Induction of lethality in wt and caspase-13=3 mice by
TNF+GalN. Wt mice (open symbols) and caspase-13=3 mice (closed
symbols) were challenged i.p. with 20 mg GalN in combination with
0.1 Wg mTNF (a) or 0.5 Wg mTNF (O). Lethality was evaluated up
to 48 h. No further deaths occurred.
Fig. 2. Induction of lethality in wt and caspase-13=3 mice by anti-
Fas. Wt mice (open symbols) and caspase-13=3 mice (closed sym-
bols) were challenged i.v. with 5 Wg anti-Fas (a) or 15 Wg anti-Fas
(O). Lethality was evaluated up to 48 h. No further deaths oc-
curred.
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wt and caspase-13=3 mice after the challenge with TNF/GalN
or anti-Fas. Livers were completely black because of in¢ltra-
tion of erythrocytes. Table 2 illustrates that apoptosis oc-
curred in hepatocytes after a challenge with TNF+GalN or
anti-Fas, both in wt and caspase-13=3 mice. No apoptosis was
detected after injection with GalN or mTNF. Table 2 also
shows that no signi¢cant di¡erences within treatment groups,
between wt and caspase-13=3 mice were found (Ps 0.05).
This was expected because of visible liver destruction when
livers were removed. Concerning the ALT levels, we found
that TNF+GalN and anti-Fas induced a dramatic release of
ALT in both types of mice. GalN and TNF alone induced no
over-background levels. These results suggest that caspase-1
de¢ciency has no e¡ect on the induction of apoptosis in both
the TNF/GalN and the anti-Fas model.
3.4. Caspase-13=3 mice still show the DNA ladder pattern after
a challenge with TNF/GalN or anti-Fas
A hallmark of apoptosis is the presence of DNA ladder
patterns that originate from DNA cleavage by an endonu-
clease, which cleaves between the nucleosomes resulting in
fragments of multimers of 180 bp. As a con¢rmation of the
results obtained by cell death ELISA, DNA was isolated from
the liver homogenates, obtained in the experiment of Table 2,
and analyzed on gel electrophoresis as described in Section 2.
Fig. 3 shows DNA ladders in mice treated with TNF+GalN
or anti-Fas in caspase-13=3 mice, as well as in control mice.
No ladder pattern was seen in mice treated with PBS, GalN or
mTNF. The results of this experiment con¢rm the data ob-
tained by ELISA.
4. Discussion
In order to study the involvement of caspase-1 in apoptosis
induced in vivo, we made use of recently generated caspase-
13=3 mice [7]. Data about a possible involvement of caspase-1
in TNF- and anti-Fas-induced apoptosis were available
[11,12] but the experiments either involved overexpression of
caspase-1 or inhibition of apoptosis by caspase inhibitors and
not speci¢c caspase-1 inhibitors. For that reason, it could not
be concluded whether only caspase-1 plays the lethal role or
rather the entire family of caspases.
In this study, we demonstrate that caspase-13=3 mice are
equally sensitive to a lethal challenge with TNF+GalN or
anti-Fas as the control mice. Furthermore, caspase-13=3
mice underwent apoptosis of hepatocytes and displayed high
levels of ALT in the serum to the same extent as control mice.
One typical feature of apoptosis, namely the appearance of
DNA ladders, also occurred in these caspase-13=3 mice. We
conclude from these data that caspase-1 seems not to be in-
volved in the apoptosis induced by TNF+GalN or anti-Fas.
These data contradict the results reported earlier. However, in
in vitro experiments it was found that all caspases were
blocked by the inhibitors [11], whereas in our experiments
only caspase-1 is absent. Recently, studies performed with
tetrapeptide caspase inhibitors demonstrated that Ac-
YVAD-cmk (claimed to be a caspase-1 inhibitor) protected
against the lethality and the induction of liver damage evoked
by anti-Fas [13]. It was also published that the broad spec-
trum caspase inhibitor zVAD-fmk confers protection against
anti-Fas-induced lethality and liver failure [14] and, ¢nally,
that zVAD-fmk prevents anti-Fas- and TNF+GalN-induced
lethality and apoptosis [15] in mice. In the di¡erent studies
reported, the tetrapeptide caspase inhibitors protect against an
i.v. challenge with 10 Wg anti-Fas, which is comparable to the
dose we used. These data contradict our results, but we be-
lieve that the inhibitors are ‘speci¢c’ for a family of caspases
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Table 2
DNA fragmentation of hepatocytes and the release of ALT in wt and caspase-13=3 mice after a lethal challenge with TNF/GalN or anti-Fas
Challenge Mice DNA Fragmentation Serum ALT
PBS Caspase-1= 100 þ 7 32 þ 14
0.5 Wg mTNF+20 mg GalN Caspase-1= 955 þ 54 5156 þ 4358
0.5 Wg mTNF Caspase-1= 130 þ 50 47 þ 14
20 mg GalN Caspase-1= 176 þ 57 72 þ 27
15 Wg anti-Fas Caspase-1= 1014 þ 32 4991 þ 1020
PBS Caspase-13=3 100 þ 9 41 þ 11
0.5 Wg mTNF+20 mg GalN Caspase-13=3 987 þ 39 4368 þ 3158
0.5 Wg mTNF Caspase-13=3 96 þ 19 52 þ 19
20 mg GalN Caspase-13=3 174 þ 58 66 þ 19
15 Wg anti-Fas Caspase-13=3 997 þ 77 6363 þ 225
Mice (n = 6) were injected i.p., except for anti-Fas given i.v. Livers were excised and blood was withdrawn 5 h after anti-Fas and 8 h after TNF/
GalN, TNF and GalN challenge. DNA fragmentation is expressed as percentage of the control, serum ALT as U/l.
Fig. 3. Analysis by agarose gel electrophoresis of DNA derived
from livers (1.8% agarose gel) after staining with ethidium bromide.
Lanes 1^5, wt mice; lanes 6^10, caspase-13=3 mice. Lanes 1 and 6,
PBS control; lanes 2 and 7, TNF/GalN; lanes 3 and 8, GalN; lanes
4 and 9, mTNF; lanes 5 and 10, anti-Fas.
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rather than speci¢c for just one caspase. The protection con-
ferred by these inhibitors in the di¡erent models must be seen
as an inhibition of a whole family, which is completely di¡er-
ent from the situation in caspase-13=3 mice, where only this
single caspase is absent. Functional redundancy is likely to
occur in this situation. In the human system, at least 10 casp-
ases have been identi¢ed, all of them di¡erently regulated and
with speci¢c substrates. Most certainly, the other caspases
play a more prominent role.
We conclude that caspase-1 does not play a crucial role in
the induction of apoptosis in hepatocytes of mice by
TNF+GalN or anti-Fas. We can further also state that inter-
leukin-18 and interferon-Q do not play an active role in our
models tested. The role of caspase-1 might be taken over by
the other caspases, or alternatively, caspase-1 might be irrel-
evant in the induction of apoptosis. Perhaps caspase-1 is im-
portant in other models of apoptosis, as it was reported that
thymocytes of caspase-13=3 mice completely resist anti-Fas-
induced apoptosis [6]. We are currently investigating the pos-
sible role of other caspases and are evaluating the use of
inhibitors of apoptosis in our models.
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